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Assessing methodological quality is a necessary activity
for any systematic review, including those evaluating
the evidence for studies of medical test performance.
Judging the overall quality of an individual study
involves examining the size of the study, the direction
and degree of findings, the relevance of the study, and
the risk of bias in the form of systematic error, internal
validity, and other study limitations. In this chapter of
the Methods Guide for Medical Test Reviews, we focus
on the evaluation of risk of bias in the form of
systematic error in an individual study as a distinctly
important component of quality in studies of medical
test performance, specifically in the context of estimat-
ing test performance (sensitivity and specificity). We
make the following recommendations to systematic
reviewers: 1) When assessing study limitations that
are relevant to the test under evaluation, reviewers
should select validated criteria that examine the risk of
systematic error, 2) categorizing the risk of bias for
individual studies as “low,”“ medium,” or “high” is a
useful way to proceed, and 3) methods for determining
an overall categorization for the study limitations
should be established a priori and documented clearly.
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M
edical tests are indispensible for clinicians and provide
information that goes beyond what is available by
clinical evaluation alone. Systematic reviews that attempt to
determine the utility of a medical test are similar to other
types of reviews-for example, those that examine clinical and
system interventions. In particular, a key consideration in a
review is how much influence a particular study should have
on the conclusions of the review. This chapter complements
the original Methods Guide for Effectiveness and Compara-
tive Effectiveness Reviews (hereafter referred to as the
General Methods Guide),
1 and focuses on issues of particular
relevance to medical tests, especially the estimation of test
performance (sensitivity and specificity).
The evaluation of study features that might influence the
relative importance of a particular study has often been framed
as an assessment of quality. Quality assessment—a broad term
used to encompass the examination of factors such as
systematic error, random error, adequacy of reporting, aspects
of data analysis, applicability, specifying ethics approval and
detailing sample size estimates—has been conceptualized in a
variety of ways.
2, 3 In addition, some schemes for quality
assessment apply to individual studies and others to a body of
literature. As a result, many different tools have been developed
to formally evaluate the quality of studies of medical tests;
however, there is no empirical evidence that any sort of score
based on quantitative weights of individual study features can
predict the degree to which a study is more or less “true.” In
this context, systematic reviewers have not yet achieved
consensus on the optimal criteria to assess study quality.
Two overarching questions that arise in considering
quality in the sense of “value for judgment making” are:
1) Are the results for the population and test in the study
accurate and precise (also referred to globally as the study’s
“internal validity”), and 2) is the study applicable to the
patients relevant to the review (an assessment of “external
validity” with regard to the purpose of the review)? The first
question relates to both systematic error (lack of accuracy,
here termed bias) and random error (lack of precision). The
second question distinguishes the relevance of the study not
only to the population of interest in the study (which relates
to the potential for bias) but, most importantly for a
systematic review, the relevance of the study to the
population represented in the key questions established at
the outset of the review (i.e., applicability).
This chapter is part of the Methods Guide for Medical
Test Reviews produced by the Agency for Healthcare
Research and Quality (AHRQ) Evidence-Based Practice
Centers (EPC) for AHRQ and the Journal of General
Internal Medicine. Similar to the General Methods Guide,
1
assessment of the major features that influence the impor-
tance of a study to key review questions are assessed
separately. Chapter 6 of this Guide considers the evaluation
of the applicability of a particular study to a key review
question. Chapter 7 details the assessment of the quality of a
body of evidence, and Chapter 8 covers the issue of random
error, which can be addressed when considering all relevant
studies through the use, if appropriate, of a summary
S33measure combining study results. Thus, this chapter high-
lights key issues when assessing risk of bias in studies
evaluating medical tests—systematic error resulting from
design, conduct, or reporting that can lead to over- or under-
estimation of test performance.
In conjunction with the General Methods Guide,
1 and the
other eleven chapters in this Methods Guide for Medical
Test Reviews, the objective is to provide a useful resource
for authors and users of systematic reviews of medical tests.
EVIDENCE FOR BIASES AFFECTING MEDICAL TEST
STUDIES
Before considering risk of systematic bias, it is useful to
consider the range of limitations in medical test studies. In a
series of studies of bias in the context of medical test
literature, Whiting et al. reviewed studies of the impact of a
range of specific sources of error in diagnostic test studies
conducted from 1966 to 2000.
3–5 In the review, the term
"test" was defined broadly to include traditional laboratory
tests, clinical examinations, imaging tests, questionnaires,
pathology, and measures of health status (e.g., the presence
of disease or different stages/severity of a disease).
6 Each
test included in the analysis was compared to a reference
standard, defined as the best comparator test to diagnose the
disease or health condition in question. The results of this
analysis indicated that no conclusions could be drawn about
the direction or relative magnitude of effects for these
specific biases. Although not definitive, the reviews showed
that bias does occur and that some sources of bias—
including spectrum bias, partial verification bias, clinical
review bias, and observer or instrument variation—are
particularly common in studies of diagnostic accuracy.
3 As
a guide to further work, the authors summarized the range
of quality issues arising in the reviewed articles (Table 1).
Elements of study design and conduct that may increase
the risk of bias vary according to the type of study. For
trials of tests with clinical outcomes, criteria should not
differ greatly from those used for rating the quality of
intervention studies.
1 However, medical test performance
studies differ from intervention studies in that they are
typically cohort studies that have the potential for important
sources of bias (e.g., complete ascertainment of true disease
status, adequacy of reference standard, and spectrum effect).
The next section focuses on some additional challenges in
assessing the risk of bias in individual studies of medical
test performance.
COMMON CHALLENGES
Several common challenges exist when assessing the risk of
bias in studies of medical test performance. The first
challenge is to identify the appropriate criteria to use. A
number of instruments are available for assessing many
different aspects of individual study quality—not just the
potential for systematic error, but also the potential for
random error, applicability, and adequacy of reporting.
3
Which of the existing instruments or which combination of
criteria from these instruments are best suited to the task at
hand?
A second common challenge is how to apply each criteria
in a way that is appropriate to the goals of the review. For
example, a criteria that is straightforward for the evaluation
of laboratory studies may be less helpful when evaluating
components of the medical history or physical examination.
Authors must ensure that the review remains true to the
spirit of the criterion and is sufficiently clear to be
reproducible by others.
Inadequacy of reporting, a third common challenge, does
not in itself lead to systematic bias but limits the adequate
assessment of important risk of bias criteria. Thus, fairly or
unfairly, studies with less meticulous reporting may be
assessed as having been less meticulously performed and as
not deserving the same degree of attention given to well-
reported studies. In such cases, when a study is otherwise
judged to make a potentially important contribution,
reviewers may need to contact the study’s authors to obtain
additional information.
PRINCIPLES FOR ADDRESSING THE CHALLENGES
Principle 1: Use Validated Criteria to Address
Relevant Sources of Bias
In selecting criteria for assessing risk of bias, multiple
instruments are available, and reviewers must choose the
one most appropriate to the task. Two systematic reviews
have evaluated quality assessment instruments specifically
in the context of diagnostic accuracy. West et al.
9 evaluated
18 tools (six scales, nine guides, and three EPC rating
systems). All of the tools were intended for use in
conjunction with other tools relevant for judging the
design-specific attributes of the study (for example, quality
of RCTs or observational studies). Three scales met all six
criteria considered important: 1) the Cochrane Working
group checklist,
10 2) the tool of Lijmer et al.,
11 and 3) the
National Health and Medical Research Council checklist.
12
In 2005, Whiting et al. undertook a systematic review
and identified 91 different instruments, checklists, and
guidance documents.
4 Of these 91 quality-related tools, 67
were designed specifically for diagnostic accuracy studies
and 21 provided guidance for interpretation, conduct,
reporting, or lists of criteria to consider when assessing
diagnostic accuracy studies. The majority of these 91 tools
did not explicitly state a rationale for inclusion or exclusion
of items; neither have the majority of these scales and
S34 Santaguida et al.: Chapter 5: Assessing Risk of Bias JGIMchecklists been subjected to formal test-retest reliability
evaluation. Similarly, the majority do not provide a
definition of the components of quality considered in the
tool. These variations are a reflection of inconsistency in
understanding quality assessment within the field of
evidence-based medicine. The authors did not recommend
any particular checklist or tool, but rather used this
evaluation as the basis to develop their own checklist, the
Quality Assessment of Diagnostic Accuracy Studies (QUA-
DAS).
The QUADAS checklist attempted to incorporate the
sources of bias and error that had some empirical basis and
validity.
6–8 This tool contains elements of study limitations
beyond those concerned with risk of systematic bias; it also
includes questions related to reporting. An updated version
of this scale, called QUADAS-2, identifies four key
domains (patient selection, index test(s), reference standard,
and flow and timing), which are each rated in terms of risk
of bias.
13 The updated checklist is shown in Table 2.
We recommend that reviewers use criteria that assess
the risk of systematic error that have been validated to
some degree from an instrument like QUADAS-2. Chap-
ters 6 and 8 discuss applicability and random error, which
are other important aspects of quality assessment. In
Table 1. Commonly Reported Sources of Systematic Bias in Studies of Medical Test Performance
Source of systematic bias Description
Population
Spectrum effect Tests may perform differently in various samples. Therefore, demographic features
or disease severity may lead to variations in estimates of test performance
Context bias Prevalence of the target condition varies according to setting and may affect estimates
of test performance. Interpreters may consider test results to be positive more
frequently in settings with higher disease prevalence, which may also affect estimates
of test performance
Selection bias The selection process determines the composition of the study sample. If the selection
process does not aim to include a patient spectrum similar to the population in which
the test will be used, the results of the study may not accurately portray the results for
the identified target population
Test protocol: materials and methods
Variation in test execution A sufficient description of the execution of index and reference standards is important
because variation in measures of diagnostic accuracy result from differences in test
execution
Variation in test technology When the characteristics of a medical test change over time as a result of technological
improvement or the experience of the operator of the test, estimates of test performance
may be affected
Treatment paradox Occurs when treatment is started on the basis of the knowledge of the results of the
index test, and the reference standard is applied after treatment has started
Disease progression bias Occurs when the index test is performed an unusually long time before the reference standard,
so the disease is at a more advanced stage when the reference standard is performed
Reference standard and verification procedure
Inappropriate reference standard Errors of imperfect reference standard bias the measurement of diagnostic accuracy of the
index test
Differential verification bias Part of the index test results is verified by a different reference standard
Partial verification bias Only a selected sample of patients who underwent the index test is verified by
the reference standard
Interpretation
Review bias Interpretation of the index test or reference standard is influenced by knowledge of the
results of the other test. Diagnostic review bias occurs when the results of the index test
are known when the reference standard is interpreted. Test review bias occurs when results
of the reference standard are known while the index test is interpreted
Clinical review bias Availability of clinical data such as age, sex, and symptoms, during interpretation of test
results may affect estimates of test performance
Incorporation bias The result of the index test is used to establish the final diagnosis
Observer variability The reproducibility of test results is one determinant of the diagnostic accuracy of an
index test. Because of variation in laboratory procedures or observers, a test may not
consistently yield the same result when repeated. In two or more observations of the same
diagnostic study, intraobserver variability occurs when the same person obtains different
results, and interobserver variability occurs when two or more people disagree
Analysis
Handling of indeterminate results A medical test can produce an uninterpretable result with varying frequency
depending on the test. These problems are often not reported in test efficacy studies;
the uninterpretable results are simply removed from the analysis. This may lead to biased
assessment of the test characteristics
Arbitrary choice of threshold value The selection of the threshold value for the index test that maximizes the sensitivity
and specificity of the test may lead to over-optimistic measures of test performance.
The performance of this cutoff in an independent set of patients may not be the same
as in the original study
S35 Santaguida et al.: Chapter 5: Assessing Risk of Bias JGIMaddition to disregarding irrelevant items, systematic
reviewers may also need to add additional criteria from
other standardized checklists such as Standards for
Reporting of Diagnostic Accuracy (STARD)
14 or Strengthen-
ing the Reporting of Genetic Association Studies
(STREGA),
15 (an extension of the Strengthening the
Reporting of Observational Studies in Epidemiology
[STROBE]).
16
Principle 2: Standardize the Application
of Criteria
In order to maintain objectivity in an otherwise subjective
process, it is useful to standardize the application of criteria.
There is little empirical evidence to inform decisions about
this process. Thus, we recommend that the review team
establish clear definitions for each criterion. This approach
is demonstrated in the Illustration section below. In
addition, it can be useful to pilot the criteria definitions
with at least two reviewers. In this way, reviewers can
revise unreliable terms and measure the reliability of the
ultimate criteria.
Consistent with previous EPC guidance and other
published recommendations,
2 we suggest summarizing
study limitations across multiple items for a single study
into simple categories. Building on the guidance given in
AHRQ’s General Methods Guide,
1 we propose using the
terms “low,”“ medium,” and “high,” to rate risk of bias.
Table 3 illustrates the application of these three categories
in the context of diagnostic accuracy studies. It is useful to
have two reviewers independently assign studies to catego-
ries, and to reconcile disagreements by discussion. A crucial
point is that whatever definitions are used, reviewers should
establish the definitions in advance of the final review (a
priori) and should report them explicitly.
Principle 3: Decide When Inadequate
Reporting Constitutes a Fatal Flaw
Reviewers must also carefully consider how to handle
inadequate reporting. Inadequate reporting, in and of itself,
does not introduce systematic bias, but it does limit the
Table 3. Categorizing Individual Studies into General Quality Classes*
Category Application to randomized controlled trials Application to medical test performance studies
Low. No major features that risk
biased results
The study avoids problems such as failure to apply
true randomization, selection of a population
unrepresentative of the target patients, low dropout
rates, or analysis by intention-to-treat. Key study
features are described clearly, including the
population, setting, interventions, comparison
groups, outcome measurements, and reasons for
dropouts
RCTs are considered a high-quality study design, but
studies that include consecutive patients
representative of the intended sample for whom
diagnostic uncertainty exists may also meet this
standard. A “low risk” study avoids the multiple
biases to which medical test studies are subject (e.g.,
use of an inadequate reference standard, verifcation
bias), and key study features are clearly described,
including the comparison groups, outcomes
measurements, and characteristics of patients who
failed to be have actual state (diagnosis or
prognosis) verified
Medium. Susceptible to some
bias, but flaws not sufficient
to invalidate the results
The study does not meet all the criteria required for a
rating of low risk, but no flaw is likely to cause
major bias. The study may be missing information,
making it difficult to assess limitations and potential
problems
Application of this category to medical test
performance studies is similar to application to
RCTs
High. Significant flaws imply
biases of various types that
may invalidate the results
The study has large amounts of missing information,
discrepancies in reporting, or serious errors in
design, analysis, and/or reporting
The study has significant biases determined a priori to
be major or “fatal” (i.e., likely to make the results
either uninterpretable or invalid)
*Adapted from AHRQ’s General Methods Guide
1
Table 2. QUADAS-2 Questions for Assessing Risk of Bias in
Diagnostic Accuracy Studies*
Domain 1: Patient Selection
Was a consecutive or random sample of patients enrolled? (Yes/No/
Unclear)
Was a case-control design avoided? (Yes/No/Unclear)
Did the study avoid inappropriate exclusions? (Yes/No/Unclear)
Could the selection of patients have introduced bias? Risk: Low/High/
Unclear
Domain 2: Index Test(s) (complete for each index test used)
Were the index test results interpreted without knowledge of the
reference standard? (Yes/No/Unclear)
If a threshold was used, was it pre-specified? (Yes/No/Unclear)
Could the conduct or interpretation of the index test have introduced
bias? Risk: Low/High/Unclear
Domain 3: Reference Standard
Is the reference standard likely to correctly classify the target
condition? (Yes/No/Unclear)
Were the reference standard results interpreted without knowledge of
the results of the index test? (Yes/No/Unclear)
Could the reference standard, its conduct, or its interpretation have
introduced bias? Risk: Low/High/Unclear
Domain 4: Flow and Timing
Was there an appropriate interval between index test(s) and reference
standard? (Yes/No/Unclear)
Did all patients receive a reference standard? (Yes/No/Unclear)
Did all patients receive the same reference standard? (Yes/No/Unclear)
Were all patients included in the analysis? (Yes/No/Unclear)
Could the patient flow have introduced bias? Risk: Low/High/Unclear
*Questions related to assessing applicability were excluded here. See
the original reference for the complete scale
13
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reviewers may take a conservative approach by assuming
the worst, while others may be more liberal by giving the
benefit of the doubt.
When a study otherwise makes a potentially important
contribution to the review, reviewers may resolve issues of
reporting by contacting study authors. When it is not
possible to obtain these details, reviewers should document
that a study did not adequately report a particular criteria.
More importantly, it must be determined a priori whether
failure to report some criteria might represent a “fatal flaw”
(i.e., likely to make the results either uninterpretable or
invalid). For example, if a review is intended to apply to
older individuals yet there was no reporting of age, this
could represent a flaw that would cause the study to be
excluded from the review, or included and assessed as
“high” with regard to risk of bias. Reviewers should
identify their proposed method of handling inadequate
reporting a priori and document this carefully.
ILLUSTRATION
A recent AHRQ systematic review evaluated the accuracy
of reporting family history and the factors that were likely
to affect accuracy.
17, 18 The index test was patients’ self-
reports of their family history, and the reference standard
test could include verification of the relatives’ status from
either medical records or disease or death registries. The
methods chapter identified a single instrument (QUADAS)
to evaluate quality of the eligible studies. The reviewers
provided a rationale for their selection of items from within
this tool; they excluded four of 14 items and gave their
justifications for doing so in an appendix. Additionally, the
reviewers provided contextual examples of how each
QUADAS item had been adapted for the review. As noted
in Table 4, partial verification bias was defined in the
context of self-reported family history as the index test, and
verification by the relatives (through either direct contact,
health record, or disease/death registry) was the reference
test. The authors provided explicit rules for rating this
quality criterion as “yes,”“ no,” or “unclear”.
The systematic reviewer can choose to present ratings of
individual QUADAS criteria in tabular form as a percentage
of the studies that scored “yes,”“ no,” or “unclear” for each
criteria. The developers of the tool do not recommend using
composite scores.
6
SUMMARY
An assessment of methodological quality is a necessary
activity for authors of systematic reviews; this should include
an evaluation of the evidence for studies of medical test
Table 4. Interpretation of Partial Verification Bias: the Example of Family History
17, 18*
Modified QUADAS item (Topic/Bias) Interpretation
5. Did the whole sample or a random selection
of the sample receive verification using a reference
standard of diagnosis? (Partial verification bias)
This item concerns partial verification bias, which is a form of selection bias that
occurs when not all of the study participants receive the reference standard
(in our context, confirmation of the TRUE disease status of the relative).
Sometimes the reason only part of the sample receives the reference standard is that
knowledge of the index test results influence the decision to perform the reference
standard. Note that in the context of family history, the reference standard
can only be applied to family members or relatives. The self report by the probands
or informants is the “index test”
We consider the whole sample to be ALL relatives for which the proband or informant
provided information (including “don’t know” status)
YES: All relatives that the proband identifies/ reports upon represent the whole sample
of relatives. As such, some form of verification is attempted for all identified relatives
NO: Not all relatives receive verification via the reference standard. As such, we consider
partial verification bias to be present in the following situations:
1) Knowledge of the index test will determine which relatives are reported to have the
disease status. Often UNAFFECTED relatives do not have their disease status verified
by any method (assume proband/informant report is the true disease status); in this
case, the disease status is verified in the AFFECTED relatives only. In this situation,
the outcomes of sensitivity and specificity cannot be computed
2) Relatives for which the proband/ informant indicates “don’t know status” are excluded
and do not have their disease status verified (no reference standard testing)
3) Relatives who are DECEASED are excluded from having any verification undertaken
(no reference standard testing)
4) Relatives who are UNABLE TO PARTICIPATE in interviews or further clinical testing
are excluded from having any verification method (no reference standard testing)
UNCLEAR: Insufficient information to determine whether partial verification was present
* See text
Abbreviation: QUADAS = Quality Assessment of Diagnostic Accuracy Studies
S37 Santaguida et al.: Chapter 5: Assessing Risk of Bias JGIMperformance. Judging the overall quality of an individual
study involves examining the size of the study, the direction
and degree of findings, the relevance of the study, and the risk
of bias in the form of systematic error, internal validity, and
other study limitations. In this chapter of the Methods Guide
for Medical Test Reviews, we focus on the evaluation of
systematic bias in an individual study as a distinctly important
component of quality in studies of medical test performance.
KEY POINTS
& When assessing limitations in studies of medical tests,
systematic reviewers should select validated criteria that
examine the risk of systematic error.
& Systematic reviewers should categorize the risk of bias
for individual studies as “low,”“ medium,” or “high.”
& Two reviewers should independently assess individual
criteria as well as global categorization.
& Reviewers should establish methods for determining an
overall categorization for the study limitations a priori
and document these decisions clearly.
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